Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 24, Issue 16, 2014, Pages 3898-3902

  Honda, Eiji ^a   Ishichi, Yuji ^a   Kimura, Eiji ^a   Yoshikawa, Masato ^a   Kanzaki, Naoyuki ^a   Nakagawa, Hideyuki ^a   Terao, Yasuko ^a   Suzuki, Atsuko ^a   Kawai, Takayuki ^a   Arakawa, Yuuichi ^a   Ohta, Hiroyuki ^a   Terauchi, Jun ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

1 Aryl 1,4 diazepan 2 one compounds; Antidepressant; Monoamine reuptake inhibition; Tail suspension test; Triple reuptake inhibition

Indexed keywords

AMITIFADINE; CYCLOPROPANE DERIVATIVE; DOPAMINE; NORADRENALIN; SEROTONIN; TRIPLE REUPTAKE INHIBITOR; ANTIDEPRESSANT AGENT; MILNACIPRAN; 1,4-DIAZEPAN-2-ONE; AZEPINE DERIVATIVE; DOPAMINE UPTAKE INHIBITOR; LIGAND;

ACYLATION; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; CYCLIZATION; DOPAMINE BRAIN LEVEL; DRUG DESIGN; DRUG METABOLISM; DRUG SYNTHESIS; MOUSE; NONHUMAN; NORADRENALIN BRAIN LEVEL; PREFRONTAL CORTEX; SEROTONIN BRAIN LEVEL; STRUCTURE ACTIVITY RELATION; TAIL SUSPENSION TEST; AMIDATION; BOC PROTECTION; CHEMICAL REACTION; DEPROTECTION REACTION; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; IC50; LIPOPHILICITY; NORADRENALIN BLOOD LEVEL; REDUCTION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DEPRESSION; DOSE RESPONSE; DRUG EFFECTS; HUMAN; MOTOR ACTIVITY; ORAL DRUG ADMINISTRATION; SYNTHESIS;

ADMINISTRATION, ORAL; ANIMALS; ANTIDEPRESSIVE AGENTS; AZEPINES; DEPRESSION; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; LIGANDS; MICE; MOLECULAR STRUCTURE; MOTOR ACTIVITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84905921967     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2014.06.046     Document Type: Article

References (22)

1. L. Iversen Br. J. Pharmacol. 147 2006 S82
2. P. Tran, P. Skolnick, P. Czobor, N.Y. Huang, M. Bradshaw, A. McKinney, and M. Fava J. Psychiatr. Res. 46 2012 64
3. S. Learned, O. Graff, S. Roychowdhury, R. Moate, K.R. Krishnan, G. Archer, J.G. Modell, R. Alexander, S. Zamuner, A. Lavergne, G. Evoniuk, and E. Ratti J. Psychopharmacol. 26 2012 653
4. P. Skolnick, P. Popik, A. Janowsky, B. Beer, and A.S. Lippa Eur. J. Pharmacol. 461 2003 99
5. J.C. Nelson J. Clin. Psychiatry 64 2003 5
6. J. Prins, B. Olivier, and S.M. Korte Expert Opin. Investig. Drugs 20 8 2011 1107
7. K. Golembiowska, M. Kowalska, and F.P. Bymaster Synapse 66 2012 435
8. M.J. Millan Neurotherapeutics 6 2009 53
9. P. Skolnick, P. Krieter, J. Tizzano, A. Basile, P. Popik, P. Czobor, and A. Lippa CNS Drug Rev. 12 2 2006 123
10. P. Skolnick, P. Popik, A. Janowsky, B. Beer, and S.A. Lippa Life Sci. 73 2003 3175
11. H. Fischer, M. Kansy, and D. Bur Chimia 54 2000 640
12. M.H. Skinner, H.-Y. Kuan, A. Pan, K. Sathirakul, M.P. Knadler, C.R. Gonzales, K.P. Yeo, S. Reddy, M. Lim, M. Ayan-Oshodi, and S.D. Wise Clin. Pharmacol. Ther. 73 2003 170
13. Y. Ishichi, E. Kimura, E. Honda, M. Yoshikawa, T. Nakahata, Y. Terao, A. Suzuki, T. Kawai, Y. Arakawa, H. Ohta, N. Kanzaki, H. Nakagawa, and J. Terauchi Bioorg. Med. Chem. 21 2013 4600
14. T. Lavoisier, and J. Rodriguez Synth. Commun. 26 1996 525
15. The equalization of cis and trans isomers of amide bond was observed in the compound 5 (4:1).
16. A. Cheguillaume, S. Lacroix, and J. Marchand-Brynaert Tetrahedron Lett. 44 2003 2375
17. Predictions of metabolites were done with MetaSite using the P450 liver model. A license for MetaSite version 3.1.2 was obtained from Molecular Discovery Ltd. (http://www.moldiscovery.com).
18. For example: L. Shao, M.C. Hewitt, F. Wang, S.C. Malcolm, J. Ma, J.E. Campbell, U.C. Campbell, S.R. Engel, N.A. Spicer, L.W. Hardy, R. Schreiber, K.L. Spear, and M.A. Varney Bioorg. Med. Chem. Lett. 21 2011 1438
19. F. Micheli, P. Cavanni, R. Arban, R. Benedetti, B. Bertani, M. Bettati, L. Bettelini, G. Bonanomi, S. Braggio, A. Checchia, S. Davalli, R.D. Fabio, E. Fazzolari, S. Fontana, C. Marchioro, D. Minick, M. Negri, B. Oliosi, K.D. Read, I. Sartori, G. Tedesco, L. Tarsi, S. Terreni, F. Visentini, A. Zocchi, and L. Zonzini J. Med. Chem. 53 2010 2534
20. MOE ver.2010.10.
21. L. Steru, R. Chermat, B. Thierry, and P. Simon Psychopharmacology 85 1985 367
22. P. Bonaventure, L. Kelly, L. Aluisio, J. Shelton, B. Lord, R. Galici, K. Miller, J. Atack, T.W. Lovenberg, and C. Dugovic J. Pharmacol. Exp. Ther. 321 2007 690